at Zacks.com (Thu, 10:51AM)
"We expect upside for shares on this derisking event," Wells Fargo says, referencing data...
"We expect upside for shares on this derisking event," Wells Fargo says, referencing data released today by Celgene (CELG +7%) on Revlimid's performance in Phase III multiple myeloma trials. "We would remain buyers," analyst Brian Abrahams notes, adding that he "expects favorable detailed data at ASH."
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Thu, 8:59AM)
at Zacks.com (Tue, 4:45PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs